Comparing surgery and locoregional therapy for liver cancer with portal vein thrombosis
Official title: To Compare the Survival Differences in Patients With HCC and Portal Vein Tumor Thrombosis Treated With Liver Resection-based Therapy Versus Locoregional-based Therapy: a Prospective Cohort Study
Run by Tongji Hospital · NCT06248528 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests whether surgery or a different type of treatment is better for people with liver cancer that has spread to the portal vein.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06248528 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with a confirmed diagnosis of HCC and PVTT, who meet specific health criteria.
✕Probably not a fit
Patients with a history of other malignancies, recurrent HCC, or significant liver complications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of surgical treatment versus locoregional therapy for patients with hepatocellular carcinoma (HCC) that has invaded the portal vein, known as portal vein thrombosis (PVTT). It aims to explore the differences in treatment outcomes based on Eastern and Western medical guidelines, which currently recommend different approaches. The study will include patients aged 18-75 with specific health criteria and will assess overall survival and recurrence rates following treatment. By comparing these two treatment modalities, the research seeks to identify the most effective strategy for managing advanced HCC with PVTT.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to improved treatment strategies and outcomes for patients with advanced liver cancer.
How similar studies have gone: While there are differing treatment approaches for HCC with PVTT, this study aims to provide new insights, as the comparative effectiveness of these specific interventions has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-75 years * Pathological type is HCC, and with PVTT * No extrahepatic HCC * Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 and Child-Pugh grade A for the liver resection group * ECOG performing status of 0-2 and Child-Pugh grade A-B for the locoregional-based group * Adequate hematologic and organ function Exclusion Criteria: * Any history of other malignant tumors or recurrent HCC * Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * Any persistent serious liver resection or locoregional therapy-related complications * Esophageal and/or gastric variceal bleeding within 6 months * Inability or refusal to comply with the treatment and monitoring * Participation in other clinical trials
Where it's running
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: WanGuang Zhang
- Email: wgzhang@tjh.tjmu.edu.cn
- Phone: +8613886195965
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.